

SUPPLEMENTARY FIGURES



Supplementary Figure 1. Stratification analyses of overall survival between high- and low-risk patients in different subgroup.

Α	l	pvalue	Hazard ratio		D	pvalue	Hazard ratio	
GEO set 1	Age	< 0.001	1.638(1.258-2.134)		Age	< 0.001	1.623(1.244-2.116)	
	Gender	0.031	1.337(1.027-1.741)		Gender	0.399	1.130(0.851-1.501)	
	Smoking	0.472	1.088(0.865-1.367)		Smoking	0.565	1.074(0.842-1.371)	
	Stage	< 0.001	2.353(1.928-2.872)		Stage	0.145	1.348(0.902-2.013)	
	Т	< 0.001	1.677(1.396-2.014)		Т	0.130	1.227(0.942-1.600)	
	Ν	< 0.001	2.001(1.698-2.358)		N	0.002	1.586(1.181-2.132)	
	Risk	< 0.001	1.808(1.377-2.374)		Risk	0.003	1.524(1.155-2.012)	
				0.71 1.0 1.41 2.0 2.83 Hazard ratio				0.71 1.0 1.41 2.0 Hazard ratio
В		pvalue	Hazard ratio		Е	pvalue	Hazard ratio	
	Age	0.059	1.825(0.977-3.407)		Age	0.265	1.513(0.730-3.136)	
2	Gender	0.784	1.114(0.516-2.403)		Gender	0.872	1.067(0.486-2.340)	-
) set	Stage	0.334	1.347(0.736-2.464)		Stage	0.109	2.712(0.801-9.185)	
GEO set	Т	0.164	1.463(0.856-2.499)		Т	0.713	0.828(0.303-2.262)	
	Ν	0.762	1.247(0.299-5.202)		Ν	0.516	0.524(0.075-3.680)	
	Risk	< 0.001	3.192(1.626-6.266)		Risk	< 0.001	3.506(1.684-7.298)	
				0.50 1.0 2.0 4.0 Hazard ratio				0.12 0.25 0.50 1.0 2.0 4.0 8.0 Hazard ratio
С	1	pvalue	Hazard ratio		F	pvalue	Hazard ratio	
	Age	0.006	2.583(1.313-5.083)		Age	< 0.001	3.478(1.713-7.061)	
set 3	Gender	0.219	1.519(0.780-2.955)		Gender	0.980	1.012(0.385-2.664)	
GEO	Smoking	0.150	1.637(0.837-3.201)		Smoking	0.246	1.814(0.664-4.953)	
	Stage	< 0.001	4.232(2.175-8.236)		Stage	< 0.001	3.800(1.911-7.558)	
	Risk	< 0.001	3.649(1.814-7.339)		Risk	0.001	3.234(1.573-6.647)	
				1.0 2.0 4.0 8.0 Hazard ratio				0.50 1.0 2.0 4.0 8.0 Hazard ratio

Supplementary Figure 2. The univariate Cox regression analysis of risk score and clinical characteristics in (**A**) GEO set 1, (**B**) GEO set 2, (**C**) GEO set 3. The multivariate Cox regression analysis of risk score and clinical characteristics in (**D**) GEO set 1, (**E**) GEO set 2, (**F**) GEO set 3.



Supplementary Figure 3. Drug sensitivity analysis between high- and low-risk patients.